arrow
G

Gaia Schiavon

AstraZeneca
H指数:40
被引数:8,223

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Analytical and clinical validation of Ion Torrent™ Oncomine™ Dx Express Test for identifying PIK3CA/AKT1/PTEN-altered tumors in patients with hormone receptor-positive advanced breast cancer for treatment with capivasertib

Ion Torrent™ Oncomine™ Dx Express测试在激素受体阳性晚期乳腺癌患者中识别PIK3CA/AKT1/PTEN突变肿瘤以用于卡匹瓦司替治疗的临床与实验验证

2026-01-010
OAAI
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer

CAPItello-291研究的简明语言摘要: 激素受体阳性的晚期乳腺癌中的Capivasertib

2024-09-162
OAAI
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

Capivasertib在激素受体阳性晚期乳腺癌中的应用

2023-06-01199
OA
A View on Drug Development for Cancer Prevention
2023-04-176
OA
Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
2023-03-0121
PRE
BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC): Results from Arm 1 D + paclitaxel (P), Arm 2 D+P + capivasertib (C), and Arm 5 D+P + oleclumab (O)
2022-02-150
PRE
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection

ER阳性/HER2-negative晚期乳腺癌循环肿瘤细胞基因组改变的系列监测: 精确肿瘤生物标志物检测的可行性

2021-12-2011
OAAI
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
2021-04-1624
OAAI
Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
2020-11-0115
OAAI
Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER plus metastatic breast cancer
2020-02-150
PRE